Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.

@article{Barlin2012ProgressionfreeAO,
  title={Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.},
  author={Joyce N. Barlin and Fanny Dao and Nadim Bou Zgheib and Sarah E. Ferguson and Paul J Sabbatini and Martee L. Hensley and Katherine M. Bell-McGuinn and Jason A. Konner and William P. Tew and Carol A. Aghajanian and Dennis Chi},
  journal={Gynecologic oncology},
  year={2012},
  volume={125 3},
  pages={621-4}
}
OBJECTIVE GOG study 172 demonstrated improved progression-free (PFS) and overall (OS) survival for patients with stage III optimally debulked ovarian and peritoneal carcinoma treated with IV/IP paclitaxel and IP cisplatin compared to standard IV therapy. The inpatient administration, toxicity profile, and limited completion rate have been blamed for the lack of acceptance and widespread use of this regimen. We sought to evaluate the PFS, OS, toxicity, and completion rate of a modified… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-9 of 9 references

Similar Papers

Loading similar papers…